S. Vemuri

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

A. Chen, Z. Stadler, M. Lowery, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia

M. Geyer, S. Devlin, M. Tallman, 2020, Haematologica.

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

M. Geyer, M. Tallman, A. Rao, 2018, Blood.

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

R. Advani, A. Zelenetz, J. Friedberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.

A. Chen, Z. Stadler, M. Lowery, 2020, Journal of Clinical Oncology.

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

O. Abdel-Wahab, M. Tallman, M. Shukla, 2019, Blood.

Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.

M. Grever, O. Abdel-Wahab, A. Saven, 2022, Blood.

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

I. Lossos, V. Seshan, A. Zelenetz, 2021, Blood.

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

I. Lossos, V. Seshan, A. Zelenetz, 2020 .

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

R. Advani, A. Zelenetz, J. Friedberg, 2022, Blood.